It is the result of the comparative analysis by Health Korea News about the variation rate of out of hospital prescription amount (January~May 2009 vs. January~May 2008) of the Korean big pharmaceutical companies of which monthly prescrpition amount is more than 5 billion won.
Health Korea News, one of the Korea major online news paper released on May 17 its data analysis based on the IMS Health data.
According to this analysis of prescription rate of ETC, Chong Kun Dang(27.92%), Daewon Pharm(23.88%), Dong Wha Pharm(23.54%) and Yuhan(21.74%) have showed more than 20% increase.
And the companies which have marked more than 10% increase are as follows:
Samjin Pharm(17.22%), Samil Pharm(14.3%), Korea United Pharm(14.02%), Hanmi Pharmaceutical(13.86%), Jeil harmaceutical(12.82%) and Shinpoong (11.48%).
ILDONG Pharmaceutical(1.18%) and Boryung(1.8%) have been in stagnation in the prescription drug market.
Meanwhile, SK Chemicals and Dream Pharma have recorded negative growth, showing -6.62% and -11.4% respectively.
But SK Chemicals showed a 24.4% increase in May, ending a period of continous decrease.
In terms of a single item, Dong A Pharmceutical's new drug 'STILLEN'(31.8 billion won) showed the greatest prescription amount, followed by antithrombotics drug 'PLAVITOR'(16.8 billion won) and 'OPALMON'(15.3 billion won) and antilipemic drug 'Ripinon'(11.5 billion won).
In total out of hospital prescription amount from January to May 2009, Daewoong Pharm(175.4 billion won) was ranked 1st, followed by Hanmi(165.3billion won), Dong-A(157,8billion won), Yuhan(115.5 billionwon) and Chong Kun Dang(102,7 billion won).<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
